"Polymyalgia Rheumatica Pipeline Analysis"DelveInsight's,“Polymyalgia Rheumatica – Pipeline Insight, 2025,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in ...

Polymyalgia rheumatica has long been neglected, especially when it comes to pharmaceutical development: but why? In 2025, polymyalgia rheumatica should have a broad therapeutic armamentarium analogous ...

Polymyalgia rheumatica has been discussed extensively in the European medical literature; the article by de Sèze and his co-workers 2 is a comprehensive recent review. But only a few North ...

Home NICE Guidance Conditions and diseases Musculoskeletal conditions Hip conditions Secukinumab for treating relapsed polymyalgia rheumatica [ID6599] Awaiting development [GID-TA11806] Expected ...

Polymyalgia rheumatica and GCA are common diseases in the elderly. New classification criteria for PMR have recently been presented and will facilitate future studies on treatment and outcome of ...

Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are related conditions that almost exclusively occur in the population aged over 50 years, with an average age of onset of approximately ...

Prediction of the Course of PMR & GCA The duration of corticosteroid therapy in PMR is variable. While some patients may discontinue therapy within 1 or 2 years of disease, others have prolonged ...

Polymyalgia rheumatica (PMR) is considered to be a benign disease by some, while others think it is a more serious illness which required similar treatment to giant cell arteritis (GCA). The progress ...

Abstract and Introduction Abstract Background: the mainstay of treatment of polymyalgia rheumatica (PMR) is oral glucocorticoids, but randomized controlled trials of treatment are lacking. As a result ...

Editorial Archive Cranial Arteritis and Polymyalgia Rheumatica Published June 22, 1967 N Engl J Med 1967;276: 1442 ...